appy new year and welcome back from the holidays. It’s going to be an exciting year, but let’s take it one week at a time. Here’s what we’re looking for this week:

The (possible) conclusion of a biotech saga

Biotech giant Alexion Pharmaceuticals is in the throes of an internal investigation that saw the abrupt resignations of its CEO and head of finance in December. The issue, which relates to how Alexion marketed its biggest drug, the rare disease treatment Soliris, led the company to delay filing its financial results for the third quarter, further stoking speculation that something particularly bad is afoot. Alexion, based in New Haven, Conn., is widely expected to finally file those quarterly numbers this week, which should illuminate just what’s going on at the multibillion-dollar drug maker.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy